Filing Flows › PTC Therapeutics (PTCT) › Q4 2025
PTC Therapeutics (PTCT) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 19, 2026
PTC Therapeutics (PTCT) reported revenue of $165M for the fourth quarter 2025 (Q4 2025), -23% from a year earlier and -22% from the quarter before. Operating margin was -43.3%, net loss $135M (82.0% of revenue).
PTC Therapeutics, Q4 2025: revenue $165M (-23% year over year), operating margin -43.3%, net loss $135M, operating cash flow −$34.3M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $165M | -22% | -23% |
| Operating profit | −$71.3M | -2466% | — |
| Net earnings | −$135M | -949% | — |
| Operating cash flow | −$34.3M | — | — |
What changed
Revenue was $164.7M in Q4 2025, down 23% year over year and down 22% from the previous quarter.
Operating costs exceeded revenue by $71.3M, an operating margin of -43.3%. Total costs fell 37% while revenue fell 23%. The fastest-growing cost line was SG&A (+14%). The quarter ended with a net loss of $135.0M, after a profit of $15.9M the previous quarter. Net interest and other expense of $67.7M was the main reason.
Operating cash flow was −$34.3M. Non-cash charges added back $12.9M of depreciation and amortization and $18.5M of share-based compensation. Working capital and other items added $69.3M. Capital expenditures of $2.4M exceeded it, leaving free cash flow of −$36.6M.
Questions
What was PTC Therapeutics' revenue in the fourth quarter 2025?
PTC Therapeutics (PTCT) reported revenue of $165M for the fourth quarter 2025 (Q4 2025), -23% from a year earlier and -22% from the quarter before.
Was PTC Therapeutics profitable in the fourth quarter 2025?
Operating loss was $71.3M (-43.3% of revenue) and net loss $135M.
Source: PTC Therapeutics 10-K on SEC EDGAR.